Lifeboat Foundation

From the oxygen-carrying corpuscles in our blood to the branching neurons that govern our thoughts, our body is built of a dazzling variety of cells.

Researchers from institutions in Germany, Canada, Spain, and the US have published a comprehensive study of how many individual cells of each type there are in typical bodies.

Based on an exhaustive analysis of over 1,500 published sources, most adult males contain a total of around 36 trillion cells, while adult females tend to have some 28 trillion cells. A 10-year-old child, by comparison, would have in the region of 17 trillion.

A stem cell that contributes to vertebra formation also encourages the growth of tumours that move to the backbone from elsewhere.

Join this virtual presentation to learn the most innovative procedures available for treating heart disease.

Presented by: juan grau, MD, director, cardiothoracic surgery.

The API-AI nexus isn’t just for tech enthusiasts; its influence has widespread real-world implications. Consider the healthcare sector, where APIs can allow diagnostic AI algorithms to access patient medical records while adhering to privacy regulations. In the financial sector, advanced APIs can connect risk-assessment AIs to real-time market data. In education, APIs can provide the data backbone for AI algorithms designed to create personalized, adaptive learning paths.

However, this fusion of AI and APIs also raises critical questions about data privacy, ethical use and governance. As we continue to knit together more aspects of our digital world, these concerns will need to be addressed to foster a harmonious and responsible AI-API ecosystem.

We stand at the crossroads of a monumental technological paradigm shift. As AI continues to advance, APIs are evolving in parallel to unlock and amplify this potential. If you’re in the realm of digital products, the message is clear: The future is not just automated; it’s API-fied. Whether you’re a developer, a business leader or an end user, this new age promises unprecedented levels of interaction, personalization and efficiency—but it’s upon us to navigate it responsibly.

More noninvasive cancer treatments are being made:

A research group from Japan Advanced Institute of Science and Technology (JAIST) developed light-activatable, liquid metal (LM) nanoparticles for cancer diagnosis and treatment via photoimmunotherapy. The LM nanoparticles can target and destroy cancer cells and can be fluorescently tagged to function as reporters to identify and eliminate tumors in vivo.

Gallium (Ga)-based LM nanoparticles are promising nanoscale materials for biomedical applications due to their physicochemical properties, including flexibility, easy surface modification, efficient photothermal conversion, and high biocompatibility.

Scientists discover a biomarker in stroke survivors, suggesting that chemical changes after stroke can lead to depression. The findings may pave the way toward treatment.

Researchers have designed a molecule that kills blood cancer cells by tricking them into self-destructing, according to results of a new study. Experts say the molecule represents a new class of compounds that could have broad potential as cancer treatments.

Like a cyanide pill hidden in the teeth of a James Bond villain, human cells have a quick means of self-destruction if necessary. This natural safeguard is a way for the body to rid itself of old, damaged, or infected cells—including cancer cells.

But in many types of cancer, those means of self-destruction are subverted or blocked off. In some diffuse large B-cell lymphoma (DLBCL) tumors, for example, genes that orchestrate cell death are shut off by a protein called BCL6.

What do pacemakers, prosthetic limbs, Iron Man and flu vaccines all have in common? They are examples of an old idea that’s been gaining in significance in the last several decades: transhumanism. The word denotes a set of ideas relating to the increasing integration of humans with their technologies. At the heart of the transhuman conversation, however, lies the oldest question of all: What does it mean to be human?

When talking about transhumanism, it’s easy to get lost because the definition is imprecise. “Transhumanism” can refer to the Transhumanist (with a capital T) movement, which actively pursues a technologically enhanced future, or an amorphous body of ideas and technologies that are closing the bio-techno gap, such as a robotic exoskeleton that enhances the natural strength of the wearer.

At Arizona State University, a diverse set of researchers has been critically examining transhumanism since 2004.

CRISPR-based genome editing has the potential to treat many human genetic diseases, but achieving stable, efficient and safe in vivo delivery remains a challenge. This Review assesses current delivery systems for genome editors—focusing on adeno-associated viruses and lipid nanoparticles—and highlights data from recent clinical trials. Emerging delivery systems and ongoing challenges in the field are discussed.